non alcohlic fatty liver disease. Other diseases of liver
Conditions
Interventions
Treatment - Drugs
Placebo
Intervention 1: This randomized clinical trial will be conducted in parallel. The objective of this study is the low number of participants in this study, 60 patients with NAFLD are referred to the Me
This randomized clinical trial will be conducted in parallel. The objective of this study is the low number of participants in this study, 60 patients with NAFLD are referred to the Medical Research C
Sponsors
Food Security Research Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria were stable increases in AST and ALT greater than 50 U / L and metabolic syndrome, which includes waist circumference greater than 40 inches for men and greater than 35 inches for women, Triglycerides greater than or equal to 150 mg /dl, HDL less than 40 mg / dl for men and less than 50 mg/dl for women, Blood pressure greater than or equal to 85/135 mmHg, fasting blood glucose greater than or equal to 110 mg / dl. The participants in this study have not hepatitis C, B and Wilson disease and no history of chronic liver disease, a disease that affects the gallbladder and bile ducts. The absence of gestational, diabetes mellitus type 1 and 2, use of drugs affecting the levels of ALT (valproic acid, tamoxifen, HMG-COA reductase inhibitors, metformin, ACE 1 and ACER 1). They do not follow the diet and weight loss because weight loss effective vitamin d. Exclusion criteria included hospitalization, lack of cooperation in the study and with an acute illness.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The severity of fatty liver using abdominal ultrasound at baseline and end of study. Timepoint: Baseline and 10 weeks after intervention. Method of measurement: ultrasound.;AST and ALT liver enzymes. Timepoint: Baseline and 10 weeks after intervention. Method of measurement: Blood tests. | — |
Secondary
| Measure | Time frame |
|---|---|
| Body composition. Timepoint: baseline and 10 weeks after intervention. Method of measurement: instrument body composition.;FBS. Timepoint: baseline and 10 weeks after intervention. Method of measurement: blood test.;Lipid profile. Timepoint: baseline and 10 weeks after intervention. Method of measurement: blood test.;CRP. Timepoint: baseline and 10 weeks after intervention. Method of measurement: blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactmahdi foroughi
food security research center
Outcome results
None listed